Growth in the pharmaceutical filtration market can be attributed to factors such as the growing biopharmaceutical industry, rising R&D spending in pharmaceutical & biotechnology industries, an increasing adoption of single-use technologies, a rising number of new product launches by leading market players, increasing purity requirements in end user segments, and increasing advances in nanofiber technology. On the other hand, membrane fouling and the high capital investment required to set up new production facilities are expected to hinder market growth.
The global Pharmaceutical Filtration market is projected to reach USD 29.7 billion by 2027 from USD 10.9 billion in 2022, at a CAGR of 17.0% during the forecast period of 2022 to 2027.
The global pharmaceutical filtration market is competitive, with Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), 3M (US), Thermo Fisher Scientific Inc. (US) together major share of the global market.
Merck KGaA is a leading player of the pharmaceutical filtration market. Merck Millipore has expanded its position as the most profitable technology and solutions supplier in the pharmaceutical filtration industry by offering leading-edge products for biotech & pharmaceutical companies and for the advancement of cell and gene therapy. With a strong geographic presence, a broad portfolio of pharmaceutical filtration products, and continuous expansion in developed as well as developing regions, the company is expected to grow at a high rate in the pharmaceutical filtration market during the forecast period.
Danaher Corporation became one of the most prominent players of the pharmaceutical filtration market after its acquisition of Pall Corporation. The company operates as one of the top players in the pharmaceutical filtration market with its strong portfolio of pharma filtration solutions, including membranes, syringe filters, vacuum devices, and large-molecular capsules. Danaher Corporation has witnessed a consistent increase in its revenue in the last three financial years. This increase can be attributed to strategic agreements, acquisitions, and expansions. For instance, in the last three years, Danaher has engaged in acquisitions and agreements with Austar LifeSciences (China), Servier Laboratories (France), New Jersey Innovation Institute (US), General Electric-Life Sciences (US), and Sartorius AG (Germany).
Sartorius AG provides an extensive range of pharmaceutical filtration products for end users such as biopharmaceutical & pharmaceutical companies, CMOs, and CROs. Significant investment in R&D has enabled the company to launch products such as Sartolab RF|BT Vacuum Filtration Units for laboratory filtration applications. Further, the company has actively engaged in strategic expansions owing to the increasing demand for its products (especially with an increase in COVID-19 cases). For instance, during the past three years, Sartorius increased its geographic presence across China, the UK, South Korea, the US, Puerto Rico, and France through the establishment and expansion of manufacturing facilities and customer interaction centers to support the significant global demand for pharma filtration products, especially for development & manufacturing of COVID-19 therapies and vaccines. With a strong geographic presence and continuous expansions in developed and developing regions, the company is expected to grow in the pharmaceutical filtration market at a high rate during the forecast period.
Browse Related Reports:
Pharmaceutical Membrane Filtration Market by Product (Filter, System), Technique (Microfiltration, Nanofiltration), Material (PES, PVDF, PTFE), Application (Final Product (Sterile Filtration), Raw Material, Cell Separation, Water) - Global Forecast to 2025